Lineage Cell Therapeutics Q2 EPS Reduced by HC Wainwright

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Investment analysts at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a research note issued on Wednesday, May 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.02) per share for the quarter, down from their previous forecast of ($0.01). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.08) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q4 2026 earnings at $0.00 EPS and FY2027 earnings at ($0.07) EPS.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its earnings results on Tuesday, May 12th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The business had revenue of $1.73 million for the quarter, compared to analysts’ expectations of $3.60 million. Lineage Cell Therapeutics had a negative return on equity of 89.36% and a negative net margin of 434.44%.

Several other equities research analysts have also recently weighed in on LCTX. D. Boral Capital restated a “buy” rating and set a $3.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, May 4th. Canaccord Genuity Group assumed coverage on Lineage Cell Therapeutics in a research note on Tuesday, April 28th. They set a “buy” rating and a $9.00 target price for the company. Finally, B. Riley Financial boosted their target price on Lineage Cell Therapeutics from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $6.25.

Lineage Cell Therapeutics Stock Up 2.3%

LCTX stock opened at $1.31 on Friday. The business has a 50 day moving average price of $1.55 and a 200 day moving average price of $1.67. The stock has a market cap of $326.58 million, a price-to-earnings ratio of -4.52 and a beta of 1.60. Lineage Cell Therapeutics has a fifty-two week low of $0.45 and a fifty-two week high of $2.09.

Institutional Investors Weigh In On Lineage Cell Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LCTX. Defender Capital LLC. purchased a new stake in Lineage Cell Therapeutics in the fourth quarter valued at approximately $11,405,000. Fifth Third Bancorp purchased a new stake in Lineage Cell Therapeutics in the first quarter valued at approximately $7,268,000. Marshall Wace LLP purchased a new stake in Lineage Cell Therapeutics in the fourth quarter valued at approximately $2,275,000. Goldman Sachs Group Inc. lifted its stake in Lineage Cell Therapeutics by 894.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,438,746 shares of the company’s stock valued at $2,403,000 after buying an additional 1,294,070 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in Lineage Cell Therapeutics by 494.7% in the fourth quarter. Jane Street Group LLC now owns 1,004,794 shares of the company’s stock valued at $1,678,000 after buying an additional 835,831 shares during the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.